prednisolone has been researched along with Biliary Tract Diseases in 6 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Biliary Tract Diseases: Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, Wde C | 1 |
| Tannuri, U | 1 |
| da Silva, LF | 1 |
| Alves, VA | 1 |
| KIMURA, H | 1 |
| FUJIMIYA, M | 1 |
| WATABE, Y | 1 |
| MURAKAWA, E | 1 |
| Nishino, T | 1 |
| Toki, F | 1 |
| Oyama, H | 1 |
| Oi, I | 1 |
| Kobayashi, M | 1 |
| Takasaki, K | 1 |
| Shiratori, K | 1 |
| Chiba, A | 1 |
| Fung, WP | 1 |
| Frankfurt, AI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
6 other studies available for prednisolone and Biliary Tract Diseases
| Article | Year |
|---|---|
Effects of the administration of pentoxifylline and prednisolone on the evolution of portal fibrogenesis secondary to biliary obstruction-an experimental study in growing animals.
Topics: Animals; Biliary Atresia; Biliary Tract Diseases; Cholestasis; Common Bile Duct Diseases; Disease Mo | 2009 |
TWO CASES OF BILIARY SYSTEM DISEASES.
Topics: Biliary Tract; Biliary Tract Diseases; Cholecystitis; Cholecystography; Cysts; Duodenal Diseases; Hu | 1963 |
Biliary tract involvement in autoimmune pancreatitis.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Biliary Tract Diseases; CD4-Positive T-Lymphocy | 2005 |
[Effect of steroid hormones on excretion of bile and bilirubin. 2. Effect of steroid hormones on concentration of serum bilirubin in children with jaundice].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Betamethasone; Biliary Tract Diseases; Bilirub | 1971 |
Clinical use of corticosteroid and immunosuppressive drugs in liver disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Biliary Tract Diseases; Chemical and D | 1974 |
[The incretory function of the pancreas in various diseases of the internal organs].
Topics: Adult; Aged; Biliary Tract Diseases; Chronic Disease; Colitis; Coronary Disease; Gastritis; Glucose; | 1971 |